Immune checkpoint inhibitors in melanoma

Adam J. Cooper, Matteo S. Carlino*, Richard F. Kefford

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)

Abstract

The potential to harness the power of the immune system and effectively treat patients with metastatic melanoma is finally being realized with the advent of immune checkpoint inhibitors. These new therapies herald a new era in the treatment of melanoma with the potential to produce very durable responses and possible cure for a subset of patients, though bring with them challenges including novel toxicities and nonconventional response patterns. This article reviews the currently available immune checkpoint inhibitors, potential biomarkers to predict response and promising investigational approaches including combination therapies.

Original languageEnglish
Pages (from-to)267-284
Number of pages18
JournalMelanoma Management
Volume2
Issue number3
DOIs
Publication statusPublished - Aug 2015

Keywords

  • Anti-CTLA4
  • Anti-PD-1
  • Anti-PD-L1
  • Checkpoint inhibitor
  • Immunotherapy
  • Ipilimumab
  • Melanoma
  • Nivolumab
  • Pembrolizumab

Fingerprint

Dive into the research topics of 'Immune checkpoint inhibitors in melanoma'. Together they form a unique fingerprint.

Cite this